iBio Inc

IBIO

Company Profile

  • Business description

    iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

  • Contact

    11750 Sorrento Valley Road
    Suite 200
    San DiegoCA92121
    USA

    T: +1 979 446-0027

    E: [email protected]

    https://www.ibioinc.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    23

iBio Inc News & Analysis

stocks

Looking under the hood at Robinhood

We review some of the platform's most popular stocks on 11 different measures of equity-related risk.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,711.10125.50-1.42%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,097.061,101.11-2.19%
FTSE 10010,452.6898.49-0.93%
HKSE22,841.62453.13-1.95%
NASDAQ23,879.20550.69-2.25%
Nikkei 22557,097.592,346.62-3.95%
NZX 50 Index14,164.7682.49-0.58%
S&P 5007,175.83147.80-2.02%
S&P/ASX 2008,609.90120.50-1.38%
SSE Composite Index3,577.080.54-0.02%

Market Movers